Lead Product(s): Golimumab
Therapeutic Area: Immunology Product Name: BAT2506
Highest Development Status: Phase I Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 17, 2020
Bio-Thera has reached a licensing agreement with Pharmapark LLC, for BAT2506, its golimumab biosimilar, under which Pharmapark will have exclusive rights to distribute and market the drug with a status of a local product in Russia and other CIS countries.